{"url_path":"/sec/apge/8-k/2026-08-11/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/1974640/0001140361-26-032231-index.html","accession_number":"0001140361-26-032231","cik":"0001974640","ticker":"APGE","issuer_name":"Apogee Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1974640/0001140361-26-032231-index.html","primary_entity_key":"0001974640","primary_entity_name":"Apogee Therapeutics, Inc."},"word_count":551,"has_tables":true,"body_markdown":"Item 5.07          Submission of Matters to a Vote\nof Security Holders.\n\nOn August 11, 2026, Apogee held virtually via live webcast a special meeting of its stockholders (the “Special Meeting”) to consider matters relating to the proposed\nMerger, as described in Apogee’s Definitive Proxy Statement on Schedule 14A filed with the SEC on July 13, 2026, as amended and supplemented (the “Definitive Proxy Statement”).\n\nAs of the close of business on July 10, 2026, the record date\nestablished to determine Apogee stockholders entitled to notice of and to vote at the Special Meeting, there were 62,140,183 shares of Apogee’s voting common stock issued and outstanding. At the Special Meeting, 46,526,253 shares, or approximately\n74.87% of all outstanding shares of Apogee’s voting common stock entitled to vote at the Special Meeting, were present either in person or by proxy. At the Special Meeting, Apogee’s stockholders voted on the proposals listed below, with Apogee’s board of directors recommending a vote “FOR” each of these proposals, as further described in the Definitive Proxy Statement. The final results for the\nvotes regarding each proposal are set forth below.\n\nProposal 1: The Merger Proposal\n\nTo adopt the Merger Agreement, pursuant to which Merger Sub will merge with and into Apogee, with Apogee surviving the Merger as an indirect wholly owned subsidiary of\nAbbVie.\n\nThe following votes were cast at the Special Meeting (in person or by proxy) on the Merger Proposal:\n\nVotes For\n\n \n\nVotes\n\nAgainst\n\n \n\nAbstentions\n\n46,508,107\n\n \n\n3,885\n\n \n\n14,261\n\nThe Merger Proposal was approved by the holders of a majority of the outstanding shares of Apogee’s voting common stock, which, together with the written consent of all\nof the holders of Apogee’s non-voting common stock adopting the Merger Agreement and approving the Merger and the other transactions contemplated by the Merger Agreement, satisfies one of the closing conditions under the Merger Agreement for the\nconsummation of the Merger.\n\nProposal 2: The Compensation Proposal\n\nTo approve, on a non-binding, advisory basis, the compensation that will or may be paid, or become payable to, Apogee’s named executive officers that is based on or\notherwise relates to the Merger and/or the other transactions contemplated by the Merger Agreement.\n\n \n\nThe following votes were cast at the Special Meeting (in person or by proxy) on the Compensation Proposal:\n\nVotes For\n\n \n\nVotes\n\nAgainst\n\n \n\nAbstentions\n\n19,323,605\n\n \n\n27,123,259\n\n \n\n79,389\n\nThe Compensation Proposal was not approved by the requisite vote of Apogee stockholders required to approve such proposal. However, approval of the Compensation Proposal\nis advisory and non-binding, and is not a condition for the consummation of the Merger.\n\nProposal 3: The Adjournment Proposal\n\nThe proposal to approve the adjournment of the Special Meeting to a later date, if necessary or appropriate, to solicit additional votes if there are insufficient votes\nin favor of the adoption of the Merger Agreement at the time of the Special Meeting, was not voted upon at the Special Meeting since there were sufficient votes to approve the Merger Proposal.\n\nNo other business properly came before the Special Meeting.\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly\nauthorized.\n\n \n\nApogee Therapeutics, Inc.\n\n \n\n \n\n \n\nDated: August 11, 2026\n\nBy:\n\n/s/ Michael Henderson, M.D.\n\n \n\n \n\nName: Michael Henderson, M.D.\n\n \n\n \n\nTitle: Chief Executive Officer"}